Apocynin/paeonol - AKL Research and Development
Alternative Names: AKL-4; APPA - AKL Research and DevelopmentLatest Information Update: 28 Mar 2023
At a glance
- Originator AKL Research and development
- Developer AKL Research and development; University of Liverpool
- Class Acetophenones; Analgesics; Anti-inflammatories; Skin disorder therapies
- Mechanism of Action NF-E2-related factor 2 modulators; NF-kappa B kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoarthritis
- No development reported Scleroderma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Scleroderma in United Kingdom (PO)
- 20 Mar 2023 Pharmacodynamics data from preclinical trial in osteoarthritis released by AKL Research and development
- 01 Jun 2022 Efficacy and safety data from a phase II trial in Osteoarthritis presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)